Bedaquiline: A review of human pharmacokinetics and drug-drug interactions

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2310-2318

  van Heeswijk, R P G ^a   Dannemann, B ^b   Hoetelmans, R M W ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Clinical trials; CYP3A; HIV; Tuberculosis

Indexed keywords

BEDAQUILINE; EFAVIRENZ; ISONIAZID; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PYRAZINAMIDE; RIFAMYCIN; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; DRUG ABSORPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER DISEASE; MULTIDRUG RESISTANT TUBERCULOSIS; PROTEIN BINDING; PROTEIN LOCALIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTIFUNGAL AGENTS; ANTITUBERCULAR AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DIARYLQUINOLINES; DRUG INTERACTIONS; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84905969248     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku171     Document Type: Article

References (53)

1. WHO. Tuberculosis Fact Sheet No. 104. Geneva, Switzerland: WHO. http:// www.who.int/mediacentre/factsheets/fs104/en/index.html (6 January 2013, date last accessed).
2. Habib AG. A clinical and epidemiologic update on the interaction between tuberculosis and human immunodeficiency virus infection in adults. Ann Afr Med 2009; 8: 147-55.
3. WHO. Treatment of Tuberculosis Guidelines, Fourth Edition. Geneva, Switzerland: WHO, 2010. http://whqlibdoc.who.int/publications/2010/ 9789241547833_eng.pdf (22 August 2012, date last accessed).
4. WHO. WHO Global Task Force Outlines Measures to Combat XDR-TB Worldwide. Geneva, Switzerland: WHO, 2006. http://www.who.int/ mediacentre/news/notes/2006/np29/en/index.html (22 August 2012, date last accessed).
5. WHO. Drug- and Multidrug-resistant Tuberculosis (MDR-TB)-Frequently Asked Questions. Geneva, Switzerland: WHO, 2011. http://www.who.int/ tb/challenges/mdr/faqs/en/index.html (22 August 2012, date last accessed).
6. Orenstein EW, Basu S, Shah NS et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-61.
7. Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 2005; 73-74: 17-24.
8. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
9. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-5.
10. Diacon AH, Donald PR, Pym A et al. Randomized trial of eight weeks of bedaquiline (TMC207) for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-6.
11. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
12. Sirturo (Bedaquiline) Tablets Prescribing Information. Titusville, NJ: Janssen. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/ 204384s000lbl.pdf (9 January 2013, date last accessed).
13. Matteelli A, Carvalho ACC, Dooley KE et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010; 5: 849-58.
14. Koul A, Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007; 3: 323-4.
15. Rouan MC, Lounis N, Gevers T et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 1444-51.
16. Janssen Research and Development. Anti-Infective Drugs Advisory Committee Meeting Briefing Document. TMC207 (Bedaquiline): Treatment of Patients With MDR-TB. NDA 204-384. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf (25 September 2013, date last accessed).
17. Lounis N, Gevers T, Van den Berg J et al. Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207. J Clin Microbiol 2008; 46: 2212-5.
18. Mesens N, Steemans M, Hansen E et al. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. Toxicol In Vitro 2010; 24: 1417-25.
19. TM (Bedaquiline 100 mg Tablets) For the Treatment of Adults (≥ 18 years) as Part of Combination Therapy of Pulmonary Multi-drug Resistant Tuberculosis (MDRTB). NDA 204-384. 2012. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Anti-InfectiveDrugsAdvisoryCommittee/UCM329258.pdf (25 September 2013, date last accessed).
20. Shimada T, Yamazaki H, Mimura M et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23.
21. Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med 2001; 226: 825-30.
22. Hanumegowda UM,Wenke G, Regueiro-Ren A et al. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. Chem Res Toxicol 2010; 23: 749-55.
23. Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol 1995; 35: 763-6.
24. van Heeswijk R, Vandevoorde A, Meyvisch P et al. The pharmacokinetics of TMC207, an investigational antimycobacterial agent, in subjects with moderate hepatic impairment. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2012. Abstract A-1260. American Society for Microbiology, Washington, DC, USA. http://www.icaaconline.com/php/icaac2013abstracts/data/papers/ 2012/A/2012_A-1260.htm (25 September 2013, date last accessed).
25. Fraeyman NF, Dello CD, Belpaire FM. Alpha 1-acid glycoprotein concentration and molecular heterogeneity: relationship to oxprenolol binding in serum from healthy volunteers and patients with lung carcinoma or cirrhosis. Br J Clin Pharmacol 1988; 25: 733-40.
26. Mezey E. Liver disease and protein needs. Annu Rev Nutr 1982; 2: 21-50.
27. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 1: 115-21.
28. Zhang Y, Zhang L, Abraham S et al. Assessment of the impact of renal impairment on the systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther 2009; 85: 305-11.
29. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84: 417-23.
30. Lamba JK, Lin YS, Schuetz EG et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-94.
31. van Heeswijk R, Diacon A, Pym A et al. The pharmacokinetics (PK) of second line antituberculosis agents with and without TMC207, an investigational antimycobacterial agent, in patients with MDR-TB. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2012. Abstract A-1258. American Society for Microbiology, Washington, DC, USA. http://www. icaaconline.com/php/icaac2013abstracts/data/papers/2012/A/2012_ A-1258.htm (25 September 2013, date last accessed).
32. Rifadin (Rifampin) Capsules (150 mg, 300 mg), Injection (600 mg) Package Insert. Bridgewater, NJ: Sanofi, 2010. http://products.sanofi.us/ rifadin/Rifadin.pdf (22 August 2012, date last accessed).
33. Everitt D, Winter H, Egizi E. Pharmacokinetic interaction between the investigational anti-tuberculosis agent TMC207 and rifampicin or rifapentine. In: Abstracts of the Nineteenth International AIDS Conference, Washington DC, 2012. Abstract MOAB0304. http://www. iasociety.org/Abstracts/A200746786.aspx (25 September 2013, date last accessed).
34. Priftin (Rifapentine) Tablets (150 mg) Package Insert. Bridgewater, NJ: Sanofi, 2010. http://products.sanofi.us/priftin/Priftin.pdf (22 August 2012, date last accessed).
35. Good CE, Healan AMB, Blumer JL et al. Whole blood mycobacterial activity (WBA) of bedaquiline (BDQ, TMC207) alone and in combination with rifampicin (RIF) or rifabutin (RBT) after oral dosing of healthy volunteers. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2012. Abstract A-1257. American Society for Microbiology, Washington, DC, USA. http://www.icaaconline.com/php/icaac2013abstracts/data/papers/ 2012/A/2012_A-1257.htm (25 September 2013, date last accessed).
36. van Heeswijk R, Lachaert R, Leopold L et al. The pharmacokinetic (PK) interaction between isoniazid/pyrazinamide and TMC207, an investigational antimycobacterial agent. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract A-780. American Society for Microbiology, Washington, DC, USA.
37. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001; 45: 382-92.
38. Nishimura Y, Kurata N, Sakurai E et al. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci 2004; 96: 293-300.
39. Ethambutol Hydrochloride Tablets Package Insert. Eatontown, NJ: Versa Pharmaceutical. http://dailymed.nlm.nih.gov/dailymed/archives/ fdaDrugInfo.cfm?archiveid=14116 (22 August 2012, date last accessed).
40. Coyne KM, Pozniak AL, Lamorde M et al. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009; 23: 437-46.
41. Kantrex Injection (Kanamycin Injection) (1 g per 3 mL) Prescribing Information. http://www.rxlist.com/kantrex-drug/indications-dosage.htm (25 September 2013, date last accessed).
42. Kaletra (Lopinavir/Ritonavir) Capsules, (Lopinavir/Ritonavir) Oral Solution Package Insert. North Chicago, IL: Abbott Laboratories. http://www. rxabbott.com/pdf/kaletratabpi.pdf (22 August 2012, date last accessed).
43. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190-4.
44. Weemhoff JL, von Moltke LL, Richert C et al. Apparent mechanismbased inhibition of human CYP3A in vitro by lopinavir. J Pharm Pharmacol 2003; 55: 381-6.
45. van Heeswijk R, Vandevoorde A, Meyvisch P et al. The effect of lopinavir/ ritonavir on the pharmacokinetics of TMC207, an investigational antimycobacterial agent. In: Abstracts of Eighteenth International AIDS Conference, Vienna, Austria, 2010. Abstract WEPE0097.
46. Viramune (Nevirapine) Tablets, Oral Suspension Package Insert. Ridgfield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. http://bidocs.boehringeringelheim. com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing+Information/PIs/Viramune/Viramune.pdf (22 August 2012, date last accessed).
47. van Heeswijk R, Vandevoorde A, Meyvisch P et al. The effect of nevirapine on the pharmacokinetics of TMC207, an investigational antimycobacterial agent. In: Abstracts of the Sixth International AIDS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, 2011. Abstract MOPE172.
48. Sustiva (Efavirenz) Capsules and Tablets Package Insert. Princeton, NJ: Bristol-Myers Squibb Company. http://packageinserts.bms.com/pi/ pi_sustiva.pdf (22 August 2012, date last accessed).
49. Dooley KE, Park JG, Swindells S et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group study A5267. J Acquir Immune Defic Syndr 2012; 59: 455-62.
50. Svensson EM, Aweeka F, Park JG et al. Model-based estimates of the effects on bedaquiline pharmacokinetics and suggested dose adjustments for patients co-infected with HIV and tuberculosis. Antimicrob Agents Chemother 2013; 57: 7280-7.
51. Stoch SA, Friedman E, Maes A et al. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol 2009; 49: 398-406.
52. van Heeswijk R, Lachaert R, Leopold L et al. The effect of CYP3A4 inhibition on the clinical pharmacokinetics of TMC207. In: Abstracts of the Thirty-eighth Union World Conference on Lung Health, Cape Town, South Africa, 2007. Abstract PS-71358-11.
53. Lehr T, Staab A, Trommeshauser D et al. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Clin Pharmacokinet 2010; 49: 53-66.